Literature DB >> 20607272

Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.

Kensuke Shiga, Reiko Mizutani, Reina Isayama, Chihiro Shimazaki, Takahiko Tokuda, Masanori Nakagawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20607272     DOI： 10.1007/s00415-010-5642-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

Review 1.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

2.  Amyloid myopathy: clinicopathologic study of 16 cases.

Authors:  R A Prayson
Journal:  Hum Pathol       Date:  1998-05       Impact factor: 3.466

3.  Early sarcolemmal dysfunction in skeletal muscle amyloidosis.

Authors:  C Doriguzzi; T Mongini; W Troni; G Monga
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

4.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.

Authors:  Efstathios Kastritis; Ashutosh D Wechalekar; Meletios A Dimopoulos; Giampaolo Merlini; Philip N Hawkins; Vittorio Perfetti; Julian D Gillmore; Giovanni Palladini
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

5.  Amyloid myopathy: an underdiagnosed entity.

Authors:  S Spuler; A Emslie-Smith; A G Engel
Journal:  Ann Neurol       Date:  1998-06       Impact factor: 10.422

6.  Myopathy in primary systemic amyloidosis.

Authors:  M A Gertz; R A Kyle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

7.  Amyloid myopathy: characteristic features of a still underdiagnosed disease.

Authors:  John E Chapin; Mario Kornfeld; Alexis Harris
Journal:  Muscle Nerve       Date:  2005-02       Impact factor: 3.217

8.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.